Apratastat

{{Drugbox | Verifiedfields = changed | verifiedrevid = 477002123 | IUPAC_name = (2S)-2-[[3-(2,6-dichlorophenyl)-2-oxo-5-oxazolidinyl]methyl]-4-methylpentanoic acid | image = Apratastat.svg | width = 200 | CAS_number = 289656-42-2 | PubChem = 6918495 | ChemSpiderID = 5293733 | UNII = 0T3F4QF6V6 | KEGG = D02995 | ChEMBL = 2103870 | C=15 | H=17 | Cl=2 | N=1 | O=4 | smiles = CC(C)C(C(=O)O)CN1C(=O)C(C2=C(C=CC=C2Cl)Cl)O1 | StdInChI = 1S/C15H17Cl2NO4/c1-8(2)12(15(20)21)7-18-13(19)11(22-14(18)23)9-5-3-4-6-10(9)16/h3-6,8,11-12H,7H2,1-2H3,(H,20,21) | StdInChIKey = ZQZQXJXKZQZQXJ-UHFFFAOYSA-N }}

Apratastat is a pharmaceutical compound that was investigated for its potential use as an anti-inflammatory agent. It belongs to a class of drugs known as matrix metalloproteinase inhibitors (MMP inhibitors), which are designed to inhibit the activity of matrix metalloproteinases (MMPs). MMPs are enzymes that play a role in the breakdown of extracellular matrix components and are involved in various physiological and pathological processes, including tissue remodeling, inflammation, and cancer metastasis.

Mechanism of Action

Apratastat functions by inhibiting the activity of MMPs, particularly those involved in the inflammatory process. By blocking these enzymes, apratastat aims to reduce the degradation of the extracellular matrix, thereby decreasing inflammation and tissue damage. This mechanism makes it a potential therapeutic agent for conditions characterized by excessive inflammation and tissue destruction, such as rheumatoid arthritis.

Clinical Development

Apratastat was developed by Bristol-Myers Squibb and underwent clinical trials to evaluate its efficacy and safety in treating inflammatory diseases. However, despite initial promise, the development of apratastat was discontinued. The reasons for discontinuation included insufficient efficacy in clinical trials and the emergence of adverse effects that outweighed the potential benefits.

Pharmacokinetics

The pharmacokinetic profile of apratastat was studied during its clinical development. It was found to have a moderate half-life, allowing for potential once or twice daily dosing. The drug was primarily metabolized in the liver and excreted via the kidneys.

Adverse Effects

During clinical trials, apratastat was associated with several adverse effects. Common side effects included gastrointestinal disturbances, such as nausea and diarrhea. More serious adverse effects included liver enzyme elevations, which led to concerns about hepatotoxicity. These safety concerns contributed to the decision to halt its development.

Conclusion

While apratastat showed potential as an anti-inflammatory agent, its development was ultimately discontinued due to safety concerns and lack of sufficient efficacy. The case of apratastat highlights the challenges in developing MMP inhibitors as therapeutic agents, particularly in balancing efficacy with safety.

Also see

• Matrix metalloproteinase
• Rheumatoid arthritis
• Drug development
• Pharmacokinetics